Favourable outcomes of peptide receptor radiotherapy (PRRT) of neuroendocrine tumours have been reported during the last years. Still, there are uncertainties on the radionuclides to be used, the treatment planning, and the indication in patients with a high proliferation rate.This case report describes a patient with a high tumour burden of poorly differentiated neuroendocrine carcinoma of unknown primary with a proliferation rate in liver metastases up to 50%, undergoing fractionated treatment with 7 cycles of (177)Lu-DOTA-octreotate (7.4 GBq each) after disease progression on two different chemotherapy regiments. Based on initial staging scintigraphy, somatostatin receptor expression was very high.Longitudinal dosimetry studies during therapy indicated ongoing increases in tumour-to-organ ratios that coincided with an objective response.We conclude that fractionated therapy with (177)Lu-DOTA-octreotate should be considered a treatment option also for those patients with large tumours, high proliferation, and high receptor expression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360199 | PMC |
| http://dx.doi.org/10.7150/thno.3594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3).
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, Saarland University, Homburg, Germany.
Article Synopsis
- A 60-year-old woman was diagnosed with advanced small bowel neuroendocrine tumor (NET G3) that had spread to the liver and was showing aggressive metabolic activity.
- After initial treatment with chemotherapy, her disease progressed, leading to the use of targeted therapy called PRRT, combining 177Lu-DOTA-octreotate and 225Ac-DOTA-octreotate, which stabilized her condition.
- A novel treatment with 225Ac-DOTA-LM3, a somatostatin receptor antagonist, resulted in an improved treatment response, marking the first documented evidence that this approach may be more effective than standard treatments for this type of cancer.
Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
Br J Radiol
October 2021
Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon, India.
Objective: The aim of the present study was to perform calculation of the absorbed doses to organs at risk and to neuroendocrine tumors and to determine whether hepatic intra-arterial (IA) injection of Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) would achieve higher intratumoral concentrations than standard intravenous administration of Lu-DOTATATE.
Methods: 29 patients with Grade I-II, inoperable, metastatic gastro-entero-pancreatic neuroendocrine tumor (GEPNET) were prospectively identified and enrolled for the study. 15 patients of GEPNETs with liver-dominant metastatic disease and less than 3 sites of extrahepatic metastatic disease were administered a single dose of Lu-DOTATATE therapy through the selective catheterization of the hepatic artery (IA group).
Patient external dose rate after Lu-DOTATATE therapy: factors affecting its decrease and predictive value.
Int J Med Sci
December 2021
Nuclear Medicine, GH Tenon-St Antoine and Sorbonne Université, Paris, France.
Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE (oxodotreotide) results in external radiation exposure from the patient. In the PREELU observational prospective study, we determined the equivalent dose rate at 1 m of the patient (EDR-1m) for a period following PRRT. The main objective was to predict which patients could be discharged from the hospital at approximately 3 h after the administration of Lu-DOTATATE, i.
View Article and Find Full Text PDFFeasibility and Therapeutic Potential of Peptide Receptor Radionuclide Therapy for High-Grade Gliomas.
Clin Nucl Med
May 2021
The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences.
Purpose: This pilot study tested the principle that 177Lu-DOTATATE may be applied to patients with high-grade gliomas (HGGs) that are either inoperable or refractory to the standard conventional treatments and also assessed whether this approach could be a viable therapeutic plan in this dilemma.
Methods: In this prospective study, 16 subjects experiencing HGGs that were either inoperable or refractory to the standard conventional treatments were included. All the patients checked for somatostatin receptor expression on the tumors.
Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Clin Nucl Med
July 2021
The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr.
Background: Recent evidence has demonstrated high expression of somatostatin receptors in neuroblastoma (NB) cells. Because of this, we endeavored to evaluate the diagnostic performance and clinical efficacy of 68Ga-DOTATATE PET/CT and peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE combined with chemotherapy in pediatric NB patients.
Patients And Methods: In total, 14 pediatric patients with histopathologically confirmed NB underwent 68Ga-DOTATATE PET/CT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!